4SC - Yakult starts Phase II trial; fresh 4SC-202 data
Yakult, 4SC’s development partner for resminostat in Japan, has reached two clinical development milestones. First, just two weeks after it joined 4SC’s pivotal RESMAIN study (n=150) in CTCL, the company recruited the first patient in Japan. Top-line results from the RESMAIN trial are expected in mid-2019. In addition, Yakult initiated its own Phase II study in biliary tract cancer (n=100) in combination with S-1 chemotherapy. S-1 is widely used in Japan and other Asian countries to treat patients following relapse after a 1st line chemotherapy regimen. The final data readout is expected in mid-2020. Meanwhile, at the AACR Annual Meeting in April, 4SC presented new preclinical data supporting the use of its second lead product, 4SC-202 in combination with various immunotherapy agents. Our valuation is virtually unchanged at €348 or €11.4/share.4SC is a biotechnology company that researches and develops drugs primarily for the treatment of cancer diseases. The Company has special expertise and clinical products in the field of epigenetics. 4SC's compounds aim to enable new therapeutic methods that offer improved efficacy and tolerability compared to the treatments available to date, both as monotherapy and in combination with other drugs. This approach is intended to enhance treatment benefits for affected patients, coupled with improvements to their life expectancy and quality of life. Adjusted for 1- for -5 stock split, April 2015Adjusted for 1- for -5 stock split, April 2015
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.